Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

18    Novo Nordisk    $5.3B    up 17.8%
Global revenue: $11.7B (17th); up 9.3%

R&D spend: $1.8B (16th), up 5.9%; 15.4% of rev.

Top brands: Novolog ($1.0B), Levemir ($843M), Novolog Flexpen ($779M), Victoza 3-pack ($457M), NovoSeven ($385M)

Planned launches: Degludec/DegludecPlus (diab.), rFXIII (bleeding), liraglutide (obesity), Turoctocog alfa (haem. A)

Promotional spend: $433M (14th); 8.2% of rev.

Patent expirations: N/A

The Danish diabetes giant continues to soar on North American sales of its modern insulins, in particular. As of November, the company had captured half of the total global insulin market and almost that much of the modern insulin market. Victoza, launched in 2010 for type 2 diabetes, saw meteoric growth in 2011 and became a blockbuster, but faces competition from Amylin's Bydureon and is weighing the development of a once-weekly version to fend off the challenge. The firm has high hopes for its thrice-weekly Degludec, a basal insulin that would take on Sanofi's $5-billion Lantus, and is exploring an obesity indication for Victoza, a possible gold mine. Now if only they could do something about Victoza spoke and bad press magnet Paula Deen.

Back to first page

Page 18 of 21
Share this article:

Email Newsletters

More in Features

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.